Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
| Biotechnology Industry | Healthcare Sector | Timothy Warbington CEO | NASDAQ (CM) Exchange | 22529Y200 CUSIP |
| US Country | 4 Employees | - Last Dividend | 12 Jun 2023 Last Split | - IPO Date |
Creative Medical Technology Holdings, Inc., headquartered in Phoenix, Arizona, is a pioneering force in the biotechnology industry, dedicating its efforts to the development of innovative biological therapeutics. With a focus on addressing complex medical conditions through advanced scientific approaches, the company has positioned itself at the forefront of research and treatment in several medical fields. These fields include immunotherapy, endocrinology, urology, neurology, and orthopedics. The company’s mission is to offer groundbreaking treatments in the United States, aiming to improve the quality of life for patients suffering from a variety of debilitating diseases.
CaverStem: A revolutionary treatment tailored for men experiencing erectile dysfunction. This approach utilizes stem cell therapy to offer a natural and lasting solution to this widespread condition.
FemCelz: Designed to help women combat loss of genital sensitivity and dryness, FemCelz employs cell therapy techniques to restore function and enhance well-being.
StemSpine: This regenerative stem cell procedure targets degenerative disc disease, a common source of chronic back pain, offering patients a non-surgical alternative for relief and recovery.
ImmCelz: A versatile immunotherapy platform with applications across multiple diseases. ImmCelz represents a cutting-edge approach to modulating the immune system to fight various conditions effectively.
OvaStem: Aimed at combating female infertility, OvaStem is a cell-based therapy designed to provide new hope for women struggling to conceive, particularly those affected by premature ovarian failure.
CELZ-201: Focused on treating Type 1 diabetes, this innovative product is in development to manage and potentially reverse this chronic condition through advanced cell therapy techniques.
AlloStemSpine: Developed to address chronic lower back pain, AlloStemSpine uses allogeneic stem cells to provide a regenerative solution for patients suffering from back issues without the need for invasive surgery.
Alova: A promising treatment dedicated to addressing infertility resulting from premature ovarian failure. Alova offers a novel approach to restoring fertility through advanced biomedical research.
In addition to these products, Creative Medical Technology Holdings, Inc. is actively developing a range of solutions aimed at preventing organ transplant rejection, treating kidney and liver failure, heart attacks, and Parkinson's disease. Through its sustained innovation and dedication to medical research, the company aims to deliver transformative treatments to patients around the world.